Update on SGLT2 Inhibitors - New Data Released at the American Diabetes Association

Critical Pathways in Cardiology

Volumn 16, Issue 3, 2017, Pages 93-95

  Lee, Sara ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b AcademicCME   (United States)

Author keywords

American Diabetes Association; CANVAS; CVD REAL; EMPA REG OUTCOME; SGLT2 inhibitors; type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; ERTUGLIFLOZIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LENGTH OF STAY; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; TREATMENT OUTCOME;

CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85026818385     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0000000000000125     Document Type: Review

References (16)

1. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:653789.
2. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717-725.
3. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90-100.
4. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
5. Boehringer Ingeheim Press Release. U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. boehringer-ingelheim. us. Available at: https://www.boehringer-ingelheim.us/press-release/us-fdaapproves-jardiance-empagliflozin-tablets-reduce-risk-cardiovascular-death. Accessed December 7, 2016.
6. AstraZeneca Press Release. AstraZeneca's CVD-REAL study shows SGLT- 2 inhibitors significantly reduced death and hospitalisations for heart failure versus other type-2 diabetes medicines. Available at: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/astrazeneca-s-cvd-realstudy-shows-sglt-2-inhibitors-significant-reduced-death-and-hospitalisationsfor-heart-failure-versus-other-type-2-diabetes-medicines-19032017.html. Accessed April 10, 2017.
7. AstraZeneca. AstraZeneca presents new data underpinning safety profile and real-world CV outcomes of Farxiga at ADA 2017. Published June 12, 2017. Available at: https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-new-data-underpinning-safety-profile-and-real-worldcv-outcomes-of-farxiga-at-ada-2017-12062017.html. Accessed June 21, 2017.
8. Cavender MA, Norhammar A, Birkeland KI, et al. Hospitalization for heart failure and death in new users of SGLT2 inhibitors in patients with and without cardiovascular disease-CVD-REAL study. June 2017. Available at: http://www.abstractsonline.com/pp8/#!/4297/presentation/45797. Accessed June 21, 2017.
9. Norhammar A, Eriksson JW, Bodegard J, et al. Dapagliflozin is associated with lower risk of hospitalization for kidney disease, heart failure, and all-cause death compared to DPP-4i: CVD-REAL Nordic. June 2017. Available at: http://www.abstractsonline.com/pp8/#!/4297/presentation/45964. Accessed June 21, 2017.
10. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017. [Epub ahead of print].
11. Janssen. INVOKANA® (canagliflozin) significantly reduces the combined risk of cardiovascular death, myocardial infarction and stroke in the CANVAS program. Published June 12, 2017. Available at: http://www.janssen.com/invokana-canagliflozin-significantly-reduces-combined-risk-cardiovasculardeath-myocardial. Accessed June 17, 2017.
12. Inzucchi SE, Fitchett D, Wanner C, et al. Reduction in cardiovascular (CV) death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from EMPA-REG OUTCOME. June 2017. Available at: http://www.abstractsonline.com/pp8/#!/4297/presentation/26919. Accessed June 21, 2017.
13. Zinman B, Mathieu C, Kaspers S, Mattheus M, Woerle HJ, Fitchett D. Empagliflozin (EMPA) reduces mortality in analyses adjusted for control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C), and HbA1c over time. June 2017. Available at: http://www.abstractsonline.com/pp8/#!/4297/presentation/26918. Accessed June 21, 2017.
14. Fitchett D, Mcknight J, Lee J, et al. Empagliflozin (EMPA) reduces heart failure irrespective of control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C), and HbA1c. June 2017. Available at: http://www.abstractsonline.com/pp8/#!/4297/presentation/26917. Accessed June 21, 2017.
15. Merck Newsroom. Merck and Pfizer announce that investigational SGLT-2 inhibitor ertugliflozin met primary endpoint in two phase 3 studies. Published June 10, 2017. Available at: http://www.mrknewsroom.com/news-release/diabetes/merck-and-pfizer-announce-investigational-sglt-2-inhibitor-ertugliflozin-met-p. Accessed June 21, 2017.
16. Lew JK, Pearson JT, Schwenke DO, Katare R. Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. Cardiovasc Diabetol. 2017;16:10.